Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing

Research output: Contribution to journalJournal articlepeer-review

Standard

Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. / Bjerrum, L; Larsen, J; Kragstrup, J.

In: Scandinavian Journal of Primary Health Care, Vol. 19, No. 3, 09.2001, p. 158-62.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Bjerrum, L, Larsen, J & Kragstrup, J 2001, 'Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing', Scandinavian Journal of Primary Health Care, vol. 19, no. 3, pp. 158-62. https://doi.org/10.1080/028134301316982379

APA

Bjerrum, L., Larsen, J., & Kragstrup, J. (2001). Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. Scandinavian Journal of Primary Health Care, 19(3), 158-62. https://doi.org/10.1080/028134301316982379

Vancouver

Bjerrum L, Larsen J, Kragstrup J. Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. Scandinavian Journal of Primary Health Care. 2001 Sep;19(3):158-62. https://doi.org/10.1080/028134301316982379

Author

Bjerrum, L ; Larsen, J ; Kragstrup, J. / Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. In: Scandinavian Journal of Primary Health Care. 2001 ; Vol. 19, No. 3. pp. 158-62.

Bibtex

@article{524314e50b3941cca182b7b531e09b04,
title = "Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing",
abstract = "OBJECTIVE: To analyse the effect of guidelines accompanied by changes in reimbursement rules for the prescription of lipid-lowering drugs (LLDs).DESIGN: Observational study focusing on LLD use before (1994-98) and after an intervention (1999).SETTING: Guidelines were developed by the Danish College of General Practitioners and focused on prevention of cardiovascular heart disease (CHD). Guidelines were sent out and changes in reimbursement took place in December 1998. Prescriptions for LLDs were extracted from a population-based prescription database (Odense University Pharmacoepidemiological Database, OPED) covering 10% of the Danish population (470,000 inhabitants).MAIN OUTCOME MEASURES: Incidence rate and 1 year prevalence rate (annual prevalence) of LLD use.RESULTS: The incidence of LLD use increased significantly in the year following the intervention. Incidence rate ratio (after/before) was 1.43 (CI 1.35-1.52). The annual prevalence of LLD use in the population increased by 0.4% after the intervention (0.2% before). The corresponding figure for patients with diabetes mellitus (treated with insulin or oral anti-diabetics) was 2.3% after the intervention (1.2% before), and for patients with CHD (treated with vasodilators) 8.1% after the intervention (5.0% before).CONCLUSION: Guidelines accompanied by a change in reimbursement rules had a significant influence on the prescribing of lipid-lowering drugs.",
keywords = "Aged, Coronary Disease/etiology, Denmark, Diabetes Complications, Drug Prescriptions/economics, Drug Utilization/statistics & numerical data, Female, Humans, Hypolipidemic Agents/therapeutic use, Male, Middle Aged, Practice Guidelines as Topic, Reimbursement Mechanisms/organization & administration",
author = "L Bjerrum and J Larsen and J Kragstrup",
year = "2001",
month = sep,
doi = "10.1080/028134301316982379",
language = "English",
volume = "19",
pages = "158--62",
journal = "Scandinavian Journal of Primary Health Care",
issn = "0281-3432",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing

AU - Bjerrum, L

AU - Larsen, J

AU - Kragstrup, J

PY - 2001/9

Y1 - 2001/9

N2 - OBJECTIVE: To analyse the effect of guidelines accompanied by changes in reimbursement rules for the prescription of lipid-lowering drugs (LLDs).DESIGN: Observational study focusing on LLD use before (1994-98) and after an intervention (1999).SETTING: Guidelines were developed by the Danish College of General Practitioners and focused on prevention of cardiovascular heart disease (CHD). Guidelines were sent out and changes in reimbursement took place in December 1998. Prescriptions for LLDs were extracted from a population-based prescription database (Odense University Pharmacoepidemiological Database, OPED) covering 10% of the Danish population (470,000 inhabitants).MAIN OUTCOME MEASURES: Incidence rate and 1 year prevalence rate (annual prevalence) of LLD use.RESULTS: The incidence of LLD use increased significantly in the year following the intervention. Incidence rate ratio (after/before) was 1.43 (CI 1.35-1.52). The annual prevalence of LLD use in the population increased by 0.4% after the intervention (0.2% before). The corresponding figure for patients with diabetes mellitus (treated with insulin or oral anti-diabetics) was 2.3% after the intervention (1.2% before), and for patients with CHD (treated with vasodilators) 8.1% after the intervention (5.0% before).CONCLUSION: Guidelines accompanied by a change in reimbursement rules had a significant influence on the prescribing of lipid-lowering drugs.

AB - OBJECTIVE: To analyse the effect of guidelines accompanied by changes in reimbursement rules for the prescription of lipid-lowering drugs (LLDs).DESIGN: Observational study focusing on LLD use before (1994-98) and after an intervention (1999).SETTING: Guidelines were developed by the Danish College of General Practitioners and focused on prevention of cardiovascular heart disease (CHD). Guidelines were sent out and changes in reimbursement took place in December 1998. Prescriptions for LLDs were extracted from a population-based prescription database (Odense University Pharmacoepidemiological Database, OPED) covering 10% of the Danish population (470,000 inhabitants).MAIN OUTCOME MEASURES: Incidence rate and 1 year prevalence rate (annual prevalence) of LLD use.RESULTS: The incidence of LLD use increased significantly in the year following the intervention. Incidence rate ratio (after/before) was 1.43 (CI 1.35-1.52). The annual prevalence of LLD use in the population increased by 0.4% after the intervention (0.2% before). The corresponding figure for patients with diabetes mellitus (treated with insulin or oral anti-diabetics) was 2.3% after the intervention (1.2% before), and for patients with CHD (treated with vasodilators) 8.1% after the intervention (5.0% before).CONCLUSION: Guidelines accompanied by a change in reimbursement rules had a significant influence on the prescribing of lipid-lowering drugs.

KW - Aged

KW - Coronary Disease/etiology

KW - Denmark

KW - Diabetes Complications

KW - Drug Prescriptions/economics

KW - Drug Utilization/statistics & numerical data

KW - Female

KW - Humans

KW - Hypolipidemic Agents/therapeutic use

KW - Male

KW - Middle Aged

KW - Practice Guidelines as Topic

KW - Reimbursement Mechanisms/organization & administration

U2 - 10.1080/028134301316982379

DO - 10.1080/028134301316982379

M3 - Journal article

C2 - 11697556

VL - 19

SP - 158

EP - 162

JO - Scandinavian Journal of Primary Health Care

JF - Scandinavian Journal of Primary Health Care

SN - 0281-3432

IS - 3

ER -

ID: 324187648